PHIO — Phio Pharmaceuticals Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1533040 ·
Last close
$1.01
Market Cap
$11.73M
52W High
$4.19
52W Low
$0.81
ADV30
169,377
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,268,000 | -4,138,000 | 14,307,000 | 12,996,000 | 1,705,000 |
| Mar 2026 | 0 | — | -4,167,000 | -4,003,000 | 17,412,000 | 17,031,000 | 950,000 |
| Dec 2025 | 0 | — | -2,534,000 | -2,371,000 | 21,487,000 | 21,031,000 | 1,340,000 |
| Sep 2025 | 0 | — | -2,505,000 | -2,392,000 | 11,505,000 | 10,705,000 | 1,666,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,707,000
Investing CF
$-7,000
Financing CF
$14,467,000
CapEx
$-12,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.64
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-159,057,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-11,515,000
Pretax Income TTM
$-10,932,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,220,000 | -8,698,000 | 21,487,000 | 1,340,000 | 20,147,000 | -7,979,000 |
| Dec 2024 | 0 | -7,387,000 | -7,150,000 | 5,738,000 | 1,015,000 | 4,723,000 | -7,112,000 |
| Dec 2023 | 0 | -10,698,000 | -10,826,000 | 9,364,000 | 1,634,000 | 7,730,000 | -10,749,000 |
| Dec 2022 | 0 | -11,462,000 | -11,480,000 | 12,814,000 | 1,976,000 | 10,838,000 | -12,129,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.61
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBRX | Moleculin Biotech, Inc. | $11.73M | $0.60 | — |
| ASBP | Aspire Biopharma Holdings, Inc. | $11.67M | $8.32 | — |
| KPRX | KIORA PHARMACEUTICALS INC | $11.64M | $2.63 | — |
| CALC | CalciMedica, Inc. | $11.95M | $1.75 | — |
| VTGN | Vistagen Therapeutics, Inc. | $11.98M | $0.27 | — |
News headlines (Yahoo Finance, 1h cache)
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
2026-09-23 11:00 · Yahoo
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
2026-09-14 11:00 · Yahoo
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-11 13:00 · Yahoo
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
2026-08-06 20:05 · Yahoo
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
2026-07-22 16:30 · Yahoo
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
2026-07-21 11:00 · Yahoo
Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones
2026-07-15 15:06 · Yahoo
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
2026-06-26 11:00 · Yahoo
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
2026-06-24 11:00 · Yahoo
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
2026-06-18 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.